Z02
Drug/Probe Discovery Platform
Project Summary
The Z02 platform – Drug/Probe Discovery – led by Kamyar Hadian, Andreas Braunschweiger, Oliver Plettenburg, and Grzegorz Popowicz, will work closely with the CRC/TRR teams to develop small molecule inhibitors (drugs/probes) or PROTACs/glues against promising targets/pathways. State-of-the-art compound screening (HTS, HCS, fragment, DEL, or computational screens), biophysical methods, structural biology techniques (NMR, X-ray, cryo-EM), and medicinal chemistry for hit-to-lead development will be applied to the projects in a tailored manner to meet individual needs. The groups of this central unit combine a unique set of expertise: Hadian group (HTS, HCS, biophysical assays), Braunschweiger group (DEL screens, MedChem), Plettenburg group (MedChem, hit-to-lead), Popowicz group (fragment/computational screens, structure biology). This combined expertise will enable the Z02 Drug/Probe Discovery Platform to rapidly identify, validate and optimize hit/lead compounds or PROTACs/molecular glues.
